Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 8, 2010, Pages 1180-1185

  Cutler, Corey ^a   Kim, Haesook T ^a   Ayanian, Shaké ^b   Bradwin, Gary ^b   Revta, Carolyn ^a   Aldridge, Julie ^a   Ho, Vincent ^a   Alyea, Edwin ^a   Koreth, John ^a   Armand, Philippe ^a   Soiffer, Robert ^a   Ritz, Jerome ^a   Richardson, Paul G ^a   Antin, Joseph H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Endothelium; Sirolimus; Veno occlusive disease

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; METHOTREXATE; RAPAMYCIN; TACROLIMUS; THROMBOMODULIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; COMPARATIVE STUDY; ENDOTHELIUM INJURY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SINGLE DRUG DOSE; VEIN OCCLUSION;

BIOLOGICAL MARKERS; E-SELECTIN; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOMODULIN; VON WILLEBRAND FACTOR;

EID: 77954315191     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.02.016     Document Type: Article

References (23)

1. Ho V.T., Revta C., Richardson P.G. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant 2008, 41:229-237.
2. Cutler C., Stevenson K., Kim H.T., et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008, 112:4425-4431.
3. Ardissino D., Cavallini C., Bramucci E., et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004, 292:2727-2734.
4. Cutler C., Henry N.L., Magee C., et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:551-557.
5. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007, 109:3108-3114.
6. Jones R.J., Lee K.S., Beschorner W.E., et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987, 44:778-783.
7. Park Y.D., Yasui M., Yoshimoto T., et al. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant 1997, 19:915-920.
8. Salat C., Holler E., Kolb H.J., et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997, 89:2184-2188.
9. Kaleelrahman M., Eaton J.D., Leeming D., et al. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF). Hematology 2003, 8:91-95.
10. Gerecitano J., Mathias C., Mick R., et al. Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantation. J Hematother Stem Cell Res 2003, 12:215-223.
11. Scrobohaci M.L., Drouet L., Monem-Mansi A., et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res 1991, 63:509-519.
12. Lee J.H., Lee K.H., Kim S., et al. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transplant 1998, 22:883-888.
13. Faioni E.M., Krachmalnicoff A., Bearman S.I., et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of veno-occlusive disease of the liver. Blood 1993, 81:3458-3462.
14. Tanikawa S., Mori S., Ohhashi K., et al. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study. Bone Marrow Transplant 2000, 26:881-886.
15. Park Y.D., Yoshioka A., Kawa K., et al. Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation. Bone Marrow Transplant 2002, 29:789-794.
16. Collins P.W., Gutteridge C.N., O'Driscoll A., et al. von Willebrand factor as a marker of endothelial cell activation following BMT. Bone Marrow Transplant 1992, 10:499-506.
17. Catani L., Gugliotta L., Vianelli N., et al. Endothelium and bone marrow transplantation. Bone Marrow Transplant 1996, 17:277-280.
18. Sudhoff T., Heins M., Sohngen D., et al. Plasma levels of D-dimer and circulating endothelial adhesion molecules in veno-occlusive disease of the liver following allogeneic bone marrow transplantation. Eur J Haematol 1998, 60:106-111.
19. Imanishi T., Kobayashi K., Kuki S., et al. Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation. Atherosclerosis 2006, 189:288-296.
20. Iguchi A., Kobayashi R., Yoshida M., et al. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation. Bone Marrow Transplant 2001, 27:1173-1180.
21. Sartelet H., Toupance O., Lorenzato M., et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 2005, 5:2441-2447.
22. Richardson P.G., Murakami C., Jin Z., et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002, 100:4337-4343.
23. Benimetskaya L., Wu S., Voskresenskiy A.M., et al. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood 2008, 112:4343-4352.